ZA972403B - Extended release formulation - Google Patents

Extended release formulation

Info

Publication number
ZA972403B
ZA972403B ZA972403A ZA972403A ZA972403B ZA 972403 B ZA972403 B ZA 972403B ZA 972403 A ZA972403 A ZA 972403A ZA 972403 A ZA972403 A ZA 972403A ZA 972403 B ZA972403 B ZA 972403B
Authority
ZA
South Africa
Prior art keywords
release formulation
extended release
formulation
extended
release
Prior art date
Application number
ZA972403A
Other languages
English (en)
Inventor
Deborah Marie Sherman
John Clifton Clark
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21762972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA972403(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Prod filed Critical American Home Prod
Publication of ZA972403B publication Critical patent/ZA972403B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA972403A 1996-03-25 1997-03-19 Extended release formulation ZA972403B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1400696P 1996-03-25 1996-03-25

Publications (1)

Publication Number Publication Date
ZA972403B true ZA972403B (en) 1998-09-21

Family

ID=21762972

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA972403A ZA972403B (en) 1996-03-25 1997-03-19 Extended release formulation

Country Status (34)

Country Link
EP (2) EP2881110A1 (ko)
JP (2) JP4771565B2 (ko)
KR (1) KR101096512B1 (ko)
CN (2) CN1090018C (ko)
AR (1) AR006519A1 (ko)
AT (1) ATE257011T1 (ko)
AU (1) AU727653B2 (ko)
BR (1) BR9701304A (ko)
CA (1) CA2199778C (ko)
CO (1) CO4761054A1 (ko)
CY (1) CY2442B1 (ko)
CZ (1) CZ291637B6 (ko)
DE (1) DE69727000T2 (ko)
DK (1) DK0797991T3 (ko)
EG (1) EG24198A (ko)
ES (1) ES2210454T3 (ko)
HK (1) HK1056686A1 (ko)
HU (1) HU224617B1 (ko)
IL (1) IL120382A (ko)
IN (1) IN187337B (ko)
NO (2) NO320355B1 (ko)
NZ (1) NZ314442A (ko)
PA (1) PA8426401A1 (ko)
PE (1) PE57198A1 (ko)
PL (2) PL195564B1 (ko)
PT (1) PT797991E (ko)
RU (1) RU2176912C2 (ko)
SK (1) SK281530B6 (ko)
SV (1) SV1997000015A (ko)
TR (1) TR199700190A2 (ko)
TW (1) TW493993B (ko)
UA (1) UA44904C2 (ko)
UY (1) UY24613A1 (ko)
ZA (1) ZA972403B (ko)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
JP3379461B2 (ja) * 1998-08-06 2003-02-24 三菱電機株式会社 コア部材の積層金型装置、コア部材の積層方法および電動機
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
DE60035579T2 (de) * 1999-05-20 2008-04-17 Elan Corp. Plc Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
ES2162746B1 (es) * 1999-10-21 2003-02-16 Lipotec Sa Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US20020143211A1 (en) * 2000-10-19 2002-10-03 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochlorid, processes for preparing thereof
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
HUP0104872A3 (en) * 2001-11-13 2004-04-28 Egis Gyogyszergyar Nyilvanosan New polymorphic forms of venlafaxine, process for their preparation, pharmaceutical compositions containing them and their use
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
EP1485344A1 (en) 2002-03-28 2004-12-15 Synthon B.V. Venlafaxine besylate
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
US6696496B2 (en) 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
WO2004069228A2 (en) * 2003-02-07 2004-08-19 Omega Farma Ehf. Sustained release formulations of venlafaxine
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
DE60309565T3 (de) * 2003-05-02 2015-01-15 Dexcel Ltd. Tablettenzubereitung mit verlängerter Freisetzung von Venlafaxin
IN2003MU00504A (ko) * 2003-06-05 2005-05-13 Alembic Ltd
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP1502587B1 (en) 2003-07-30 2006-08-23 Pharmathen S.A. Sustained release formulation for Venlafaxine hydrochloride
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
EP1523979A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release pharmaceutical dosage form
DE10359154A1 (de) 2003-12-16 2005-07-28 Krka Tovarna Zdravil, D.D. Verfahren zur Herstellung von Venlafaxin und Venlafaxinhydrochlorid der Form I
JP2007520547A (ja) 2004-02-04 2007-07-26 アレムビック・リミテッド ベンラファキシン塩酸塩の徐放性コーティングされた小型錠剤
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100463676C (zh) * 2004-11-11 2009-02-25 成都康弘药业集团股份有限公司 一种盐酸文拉法辛控释片制剂及其制备方法
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US9561188B2 (en) * 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
EP2010158B1 (en) 2006-04-26 2016-02-17 Alphapharm Pty Ltd. Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
KR100791194B1 (ko) * 2006-06-12 2008-01-02 코오롱제약주식회사 염산 벤라팍신의 경구 투여용 서방성 펠렛 및 그 제조방법
US9943489B2 (en) * 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
CA2826180C (en) 2011-01-31 2020-09-01 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
CN103893151B (zh) * 2012-12-31 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
KR20200005576A (ko) 2017-05-17 2020-01-15 컨플루언스 파마슈티컬스, 엘엘씨 호모타우린 및 이의 염의 제형
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
IE60311B1 (en) 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
EP1738753B1 (en) * 1993-06-28 2008-04-23 Wyeth New treatments using phenethylamine derivatives
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada

Also Published As

Publication number Publication date
CO4761054A1 (es) 1999-04-27
HK1056686A1 (en) 2004-02-27
JPH107552A (ja) 1998-01-13
PL188444B1 (pl) 2005-02-28
IL120382A0 (en) 1997-07-13
CA2199778A1 (en) 1997-09-25
KR970064599A (ko) 1997-10-13
IN187337B (ko) 2002-03-30
HU224617B1 (hu) 2005-11-28
EP2881110A1 (en) 2015-06-10
HUP9700589A2 (en) 1997-09-29
HUP9700589A3 (en) 2001-03-28
HU9700589D0 (en) 1997-05-28
MX9701873A (es) 1997-09-30
NO320355B1 (no) 2005-11-28
EG24198A (en) 2008-10-14
CZ291637B6 (cs) 2003-04-16
NO971206D0 (no) 1997-03-14
CY2442B1 (en) 2004-11-12
DK0797991T3 (da) 2004-04-05
UA44904C2 (uk) 2002-03-15
JP2008156374A (ja) 2008-07-10
EP0797991B1 (en) 2004-01-02
ES2210454T3 (es) 2004-07-01
TR199700190A2 (xx) 1997-10-21
AR006519A1 (es) 1999-09-08
PE57198A1 (es) 1998-10-10
NZ314442A (en) 1999-06-29
PA8426401A1 (es) 2000-05-24
JP4771565B2 (ja) 2011-09-14
CN1164389A (zh) 1997-11-12
UY24613A1 (es) 2000-09-29
SV1997000015A (es) 1997-08-13
CZ77297A3 (en) 1997-11-12
DE69727000T2 (de) 2004-06-09
CA2199778C (en) 2005-12-20
SK30197A3 (en) 1997-10-08
CN1403077A (zh) 2003-03-19
PT797991E (pt) 2004-05-31
AU1640097A (en) 1997-10-02
EP0797991A1 (en) 1997-10-01
KR101096512B1 (ko) 2014-11-28
PL318954A1 (en) 1997-09-29
IL120382A (en) 2003-06-24
CN1090018C (zh) 2002-09-04
NO971206L (no) 1997-09-26
NO20050379L (no) 1997-09-26
PL195564B1 (pl) 2007-10-31
TW493993B (en) 2002-07-11
AU727653B2 (en) 2000-12-21
SK281530B6 (sk) 2001-04-09
DE69727000D1 (de) 2004-02-05
BR9701304A (pt) 1998-09-29
ATE257011T1 (de) 2004-01-15
RU2176912C2 (ru) 2001-12-20

Similar Documents

Publication Publication Date Title
EG24198A (en) Extended release formulation
GB9826662D0 (en) Controlled release formulation
IL135295A0 (en) 2-methyl-thieno-benzodiazepine formulation
ZA9510687B (en) Sustained release caffeine formulation
GB9715751D0 (en) Formulations
SG71879A1 (en) Controlled release compositions
ZA9811461B (en) New formulation
ZA9710601B (en) Novel formulation
HRP20000213B1 (en) Extended release formulation
GB2310860B (en) Stable release agents
SG71789A1 (en) Controlled release compositions
ZA985669B (en) New formulation
GB9724544D0 (en) Novel Formulation
GB2322867B (en) Release agent
GB9725061D0 (en) Revitalisation formulation
GB9706957D0 (en) Formulation
GB9915929D0 (en) Novel release latch-c-i-p
GB9615628D0 (en) Formulation
EP0935965A4 (en) SUBSTANCE AGAINST PYLORI
GB9605948D0 (en) Novel formulations
GB9711946D0 (en) Release devices
AU2003259586B9 (en) Extended release formulation
GB9404544D0 (en) Controlled release formulation
GB9624115D0 (en) Formulations
GB9721807D0 (en) Formulation